Occam Global is the executive search firm and leadership advisory partner for entrepreneurs, investors, and corporations pursuing exceptional goals in frontier technologies, including life sciences, defense, robotics, and venture capital, worldwide.
Since 2012, Occam has partnered with leading founders, CEOs, and investors across life sciences and deep tech to deliver high-performing C-suite and board leadership. From stealth startups to public markets, we run retained executive search, advise on organizational strategy, and invest alongside visionary teams building category-defining companies.
Our edge: an unmatched ability to attract exceptional business and scientific leaders, seamless access to rare talent, and a relentless commitment to results — guided by high ethics and enlightened aggression.
Whether you’re launching, leading, or investing, Occam fuels growth through the power of talent. Visit occam-global.com to learn more.
Occam was founded in 2012 on a simple yet uncommon belief: executive search could be more creative, thoughtful, and principled than the industry norm.
After a 25-year career shaping leadership at Fidelity Investments, William ”Bill” Holodnak partnered with his son, John, to build a firm defined by focus, judgment, and ethics.
From the beginning, we chose to partner closely with founders and entrepreneurial leaders as they navigate moments that define their companies. We understood that early-stage and high-growth businesses require more than resume shuffling — they require judgment calls made under incomplete information, the kind no algorithm can make for you. Today, Occam is a global executive search firm trusted by founders, boards, and investors in high-stakes leadership moments.
That judgment is built from pattern recognition — hundreds of these decisions, across every stage from founding team to post-IPO board — brought to bear on the search in front of us. It’s why investors bring us in before the problem is even fully defined, and why the leaders we place deliver proven track records, real impact, and long-term value.
We built our firm on the pillars of objectivity, undiluted ethics, and enlightened aggression.
With a process that’s rooted in relationships, data, and intellect, we’ve provided professional judgments that have made a lasting impact on our partners.
Our judgements are simultaneously inspired by instinct and pragmatism, resulting in balanced outcomes designed to endure.
New York City-based executive search firm Occam Global has placed Glenn Vraniak as CFO of eGenesis, a biotechnology company developing human-compatible engineered organs for transplantation. “eGenesis is entering a pivotal stage in our evolution as we prepare to advance our programs through clinical development and lay the foundation for future commercialization,” said Mike Curtis, CEO of eGenesis.
New York City-based executive search firm Occam Global has recruited Natalie Holles as CEO of NASDAQ-traded Aura Biosciences in Boston, MA. She succeeds Elisabet de los Pinos, the company’s founder, who stepped down from her roles as CEO and president and member of the board of directors on the same date. “We are delighted to welcome Natalie as CEO
New York City-based executive search firm Occam Global has placed Marcus Schindler as a member of the advisory board at Cradle, the enterprise-grade AI platform for protein engineering. He will help accelerate the platform’s scientific impact and drive broader adoption of AI-powered protein engineering across the life sciences industry. “Marcus is renowned for modernizing drug discovery at some
New York City-based executive search firm Occam Global has recruited Craig T. Basson as chief medical officer and president of R&D of Variant Bio, a genomics-driven AI drug discovery company in Seattle, WA. “Craig’s career uniquely spans deep human genetics, rigorous clinical science, and successful drug development at scale,” said Andrew Farnum, chief executive officer of Variant Bio. “His
In June 2026, Occam successfully recruited Glenn S. Vraniak as Chief Financial Officer of eGenesis, a biotechnology company developing a revolutionary xenotransplantation platform to address the global organ shortage. Glenn brings more than two decades of financial leadership across the life sciences industry. Prior to joining eGenesis, he served as CFO of Inversago Pharma, where he helped lead the company’s
In early 2026, Occam Global recruited Jeremy David Curuksu, PhD, as CTO of eigenblue, which recently emerged from stealth, and is developing an innovative Physical AI platform that unites machine learning, software, manufacturing, and applied engineering. Jeremy combines deep technical expertise, applied AI leadership, and academic research. He held senior scientific leadership roles at Amazon and AWS,
In early 2026, Occam Global placed Mickey Atwal, PhD as Chief Scientific Officer of eigenblue, a pioneering Physical AI company that recently emerged from stealth following the merger of Gandalv and Motius R&D. Mickey joins eigenblue following a distinguished career spanning AI, computational science, biotechnology, and advanced research. Most recently, he served as Chief Data & AI Officer
In June 2026, Occam Global recruited Kim Branson, PhD, to the Advisory Board of Cradle, a leading AI-powered protein engineering platform company. Branson is widely regarded as one of the foremost leaders in AI for drug discovery and development. As Chief AI Officer at GSK, he leads a global organization of more than 150 engineers and machine learning researchers applying
Case Studies
Read about how Occam Global is helping innovative organizations tackle their biggest executive recruitment challenges
Blog & Insights
Discover new tips, industry news and guides by Occam Global
-Latest Interview: Whit Bernard, CEO of Metsera